Biotech
News Category
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures
Shareholders of VERAXA Biotech AG approved key corporate governance and financing proposals with over 99.94% support, providing flexibility for growth...
VERAXA Biotech Advances Bispecific ADC Program Under OmniAb Collaboration, Reaching Key Milestone for VXA-222
VERAXA Biotech announced that its bispecific antibody-drug conjugate program VXA-222 has reached a key technical milestone under its collaboration wit...
Gerresheimer Opens New Plant in Zhenjiang Dagang, Doubling Production Capacity for Injectable Pharma Packaging in China
Gerresheimer has commenced operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packa...
Darwin AG Renamed to Novogenia AG to Unify Brand and Strengthen Market Position
Darwin AG has been renamed to Novogenia AG, aligning its corporate identity with its core operating brand to enhance visibility and recognition in per...
NanoViricides Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
NanoViricides moves its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, addressing a cri...
Redwood AI Corp. Added to CSE25 Index, Boosting Visibility Among Investors
Redwood AI's inclusion in the CSE25 Index signals its growth among the largest CSE-listed companies, potentially increasing investor interest and vali...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for HLP003, a treatment for major depressive disorder, with top...
Quantum BioPharma’s Lucid-MS Could Transform Multiple Sclerosis Treatment
Quantum BioPharma is developing Lucid-MS, a first-in-class drug candidate that targets myelin repair, offering a potential breakthrough for the 2.9 mi...
Drug Delivery Emerges as a Key Frontier in Oncology, Offering New Life for Existing Therapies
The $410 billion nanomedicine market is gaining traction as companies like Oncotelic Therapeutics leverage advanced drug delivery platforms to enhance...
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis, is preparing for Phase 2 trials after positive Phase 1 ...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Precision Cancer Therapy
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and dose-dependent k...
Redwood AI Corp. Leverages AI to Accelerate Chemistry R&D Across Multiple Sectors
Redwood AI Corp. uses proprietary AI platforms to accelerate chemistry research and development, potentially transforming drug discovery, defense, and...
NanoViricides Receives DRC Approval for Phase II Ebola Trial of NV-387 Oral Gummies
NanoViricides announced DRC regulatory approval to advance its Phase II Ebola trial for NV-387 Oral Gummies, the only oral Ebola treatment candidate u...
Helus Pharma Chief Medical Officer to Present at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma's CMO will discuss the company's novel serotonergic agonists at a key industry conference, highlighting its Phase 3 depression treatment ...
Onco-Innovations Advances Manufacturing Process for Cancer Drug Candidate ONC010
Onco-Innovations has initiated process development and scale-up for its proprietary drug candidate ONC010, a milestone toward IND-enabling studies and...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis, Completes Phase 1 Trials
Quantum BioPharma's LUCID-MS program shows promise in addressing the unmet need for myelin repair in multiple sclerosis, with phase 1 trials demonstra...
NeuroOne to Present at Planet MicroCap Las Vegas 2026 Conference
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing commercialization updates and milestones for it...
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
GeoVax CEO David Dodd comments on recent pharmaceutical industry acquisitions, emphasizing the growing recognition of vaccine innovation and health se...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma Ltd. discussed its lead drug candidate Lucid-MS for multiple sclerosis and its commercial product unbuzzd on the BioMedWire Podcast,...
Helus Pharma to Present at Jefferies Global Healthcare Conference
Helus Pharma announced its participation in the Jefferies Global Healthcare Conference, highlighting its progress in developing novel serotonergic ago...
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral NV-387 could be evaluated for the Bundibugyo Ebola outbreak, with its host-targeted mechanis...
SureNano Science Ltd. Positions Itself in the GLP-1 Therapy Boom with Novel Peptide GEP-44
SureNano Science Ltd. is advancing GEP-44, a GLP-1-based peptide for obesity and metabolic disorders, aiming to compete with blockbuster drugs like Oz...
Oncotelic Therapeutics Demonstrates AI Platform with 28 Million Abstracts, Positioning for Drug Discovery Market Growth
Oncotelic Therapeutics integrates 28 million scientific abstracts into its PDAOAI platform, signaling a shift in drug discovery toward AI-driven infra...
Telomir Pharmaceuticals Reports Preclinical Data Supporting Telomir-Zn for Wilson's Disease
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced oxidative stress, hepatic copper, an...
FDA Supports Lantern Pharma's HARMONIC Trial Amendments for Never-Smoker NSCLC
Lantern Pharma receives FDA support for protocol amendments in its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small c...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the ongoing Bundibugyo Ebola outbrea...
Quantum BioPharma Reports Midpoint Enrollment Milestone in MS Imaging Study, Preliminary Data Show Promise
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion
LIXTE Biotechnology Holdings announced progress in its lead oncology candidate LB-100 and strategic expansion through its Liora Technologies subsidiar...
Dogwood Therapeutics Reports First Quarter 2026 Financial Results and Pipeline Progress
Dogwood Therapeutics announced Q1 2026 financial results, highlighting enrollment of 164 patients in its Halneuron Phase 2b CINP trial with data expec...
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Innovations in blood-brain barrier penetration, such as Oncotelic’s intranasal nose-to-brain system, are poised to transform CNS therapeutics by enabl...
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Hantavirus Fatalities on Cruise Ship Draw Attention to This Little-Known Infection
Three deaths on the MV Hondius cruise ship due to hantavirus highlight the risks and need for awareness of this rare but dangerous infection.
NanoViricides Receives Orphan Drug Designation for NV-387 to Treat Measles Amid Global Outbreaks
NanoViricides announced FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 for measles, offering incentives and supporting developmen...
VolitionRx Achieves Finger-Prick Breakthrough for Nucleosome Detection in Sepsis
VolitionRx announces successful detection of nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototype, potentia...
Helus Pharma Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 major depressive disorder trial, leveraging networks to enhance ...
Ventripoint's VMS+ 4.0 Submitted for Regulatory Approval in China, Leveraging Green Channel Pathway
Ventripoint Diagnostics announced that its strategic partner Lishman Global has submitted the VMS+ 4.0 system to China's NMPA for approval under an ex...
Formycon to Report FY2025 Results and Participate in Key Investor Conferences in Q2 2026
Formycon AG invites to a conference call on its FY2025 results on April 22, 2026, and announces participation in several international investor confer...
Helus Pharma Appoints Dr. Ken Kramer as SVP of Medical Affairs, Bolstering Neuroscience Pipeline
Helus Pharma appoints Dr. Ken Kramer, a seasoned neuroscience executive, as senior vice president of medical affairs to advance its clinical-stage ser...
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update, Pivotal Phase 3 Trial for GEO-MVA Scheduled for Second Half of 2026
GeoVax Labs announced its 2025 financial results and operational highlights, emphasizing regulatory alignment with the EMA and manufacturing readiness...
Kairos Pharma Wins 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Kairos Pharma receives the Emerald honoree at the 2026 Pinnacle Awards for its innovative approach to overcoming cancer drug resistance through its le...
HeartBeam Announces Public Offering to Accelerate Cardiac AI and Commercialization Efforts
HeartBeam is launching an underwritten public offering to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system, extended-wear ...
Lixte Biotech Advances Precision Oncology With LB-100, Expands Clinical and Strategic Partnerships
Lixte Biotechnology is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance existing cancer treatments, through expanded ...
Lixte Biotech Advances Precision Oncology with LB-100, Expands Clinical Trials and Strategic Partnerships
Lixte Biotech Holdings Inc. is advancing its lead candidate LB-100, a first-in-class therapy that enhances existing cancer treatments, and has expande...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing Antiviral NV-387 Against Clade I Virus
NanoViricides announced plans to begin a Phase II clinical trial of its antiviral candidate NV-387 for MPox in the Democratic Republic of Congo, with ...
BioStem Technologies to Present at Needham Virtual Healthcare Conference, Highlighting Regenerative Medicine Innovations
BioStem Technologies will present at the 25th Annual Needham Virtual Healthcare Conference, showcasing its advanced allograft products and processing ...
Telomir Pharmaceuticals Submits IND for Telomir-1 in Triple-Negative Breast Cancer
Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Telomir-1, a novel oral therapy for advanced triple-negat...
Ketryx Launches Inaugural Validated AI Conference for Regulated Industries
Ketryx announces the Validated AI Conference, a first-of-its-kind event uniting professionals building AI in regulated environments to share practical...